Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. GenSight Biologics S.A.
  6. News
  7. Summary
    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GenSight Biologics S A : successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

10/22/2020 | 01:15am EDT

The following information is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the 'United States'), Canada, Japan or Australia, and does not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any securities in the United States, Canada, Japan or Australia. Any offers described on the website are not being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facility of a national securities exchange of, the United States. All persons residing outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition or sale of securities by them. GenSight Biologics S.A. assumes no responsibility if there is a violation of applicable law and regulations by any person.

I certify that I am not a resident of or physically present in the United States, Canada, Japan or Australia.

I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:

Disclaimer

Gensight Biologics SA published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 05:14:05 UTC


© Publicnow 2020
All news about GENSIGHT BIOLOGICS S.A.
06/10GENSIGHT BIOLOGICS S A  : Names Chief Technical Officer
MT
06/01GENSIGHT BIOLOGICS S A  : Gene Therapy Improves Visual Acuities, Analysis Shows
MT
05/25GLOBAL MARKETS LIVE : Vonovia, Amazon, Xiaomi, Apple, Huawei...
05/25GENSIGHT BIOLOGICS S A  : Says Blind Patient Partially Recovers In Phase 1/2 Stu..
MT
05/24PRESS RELEASE : Optogenetic Methods Restore Partial Vision in a Blind Patient
DJ
05/14GLOBAL MARKETS LIVE : Airbnb, Coinbase, Walt Disney,...
05/11GENSIGHT BIOLOGICS S A  : Corporate presentation, May 2021
PU
05/11GENSIGHT BIOLOGICS S A  : Corporate presentation, June 2021
PU
04/30GENSIGHT BIOLOGICS S A  : Compensation Policies
PU
04/09GENSIGHT BIOLOGICS S A  : - focused on developing and commercializing innovative..
AQ
More news
Financials
Sales 2021 13,9 M 16,8 M 16,8 M
Net income 2021 -24,2 M -29,2 M -29,2 M
Net cash 2021 5,50 M 6,66 M 6,66 M
P/E ratio 2021 -16,1x
Yield 2021 -
Capitalization 454 M 549 M 549 M
EV / Sales 2021 32,4x
EV / Sales 2022 17,1x
Nbr of Employees 25
Free-Float 98,1%
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 17,67 €
Last Close Price 9,00 €
Spread / Highest target 122%
Spread / Average Target 96,3%
Spread / Lowest Target 66,7%
EPS Revisions
Managers and Directors
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Thomas Gidoin Chief Financial Officer
Michael S. Wyzga Chairman
Magali Taiel Chief Medical Officer
Marion Ghibaudo Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.26.23%549
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966